Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior (Nasdaq: INDV) will participate in two June 2026 investor conferences. Management will attend the Jefferies Global Healthcare Conference in New York on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, hosting 1x1 and group investor meetings.
Indivior (Nasdaq: INDV) announced a $175 million accelerated share repurchase (ASR) with Barclays under its existing $400 million buyback program on May 4, 2026. Indivior will pay $175 million upfront and expects an initial delivery of 3,717,473 shares, with final settlement tied to VWAP less a discount by end of June 2026. The company said the ASR is not expected to affect its previously issued financial guidance and that up to $100 million of the authorization remains available for future repurchases.
Indivior (Nasdaq: INDV) reported Q1 2026 results and raised full‑year guidance. Q1 total net revenue was $317 million (+19% YoY) and SUBLOCADE net revenue was $232 million (+32% YoY). Adjusted EBITDA was $164 million (+112% YoY). The company completed a $500 million convertible note offering and repurchased ~3.97 million shares for $125 million, leaving $275 million available under a $400 million repurchase program.
The company ceased internal development of INDV-6001 and will not advance INDV-2000 after Phase 2; guidance ranges for 2026 were raised for revenue and Adjusted EBITDA.
Indivior (NASDAQ: INDV) will present two posters at ASAM 2026 (April 23-26) reporting real-world and observational findings on monthly extended-release buprenorphine (BUP-XR, SUBLOCADE).
Findings link higher MOUD coverage and BUP-XR use to lower fatal and non-fatal overdose proportions, and associate 3-month remission with better craving, withdrawal, pain, quality of life, and employment outcomes.
Indivior (Nasdaq: INDV) reported results from a national survey of 180 U.S. correctional professionals showing strong support for long-acting injectable (LAI) buprenorphine to reduce medication-for-opioid-use-disorder (MOUD) diversion: 88% of jail and 87% of prison respondents endorsed its potential to help.
Respondents cited staffing, custody-health coordination, operational medication challenges, cost, and limited access as barriers to MOUD implementation and sustainable delivery during incarceration and reentry.
Indivior (Nasdaq: INDV) will report first quarter 2026 financial results on Thursday, April 30, 2026 at 7:00 a.m. U.S. EDT. A live webcast presentation with CEO Joe Ciaffoni and other leaders will follow at 8:00 a.m. U.S. EDT.
Investors can access the live webcast and materials on the company’s Investors webpage; a replay will be available after the event.
Indivior (Nasdaq: INDV) released a cost impact model (March 31, 2026) estimating that monthly injectable buprenorphine (SUBLOCADE) could cut staff time and related costs for treating 100 incarcerated patients with opioid use disorder versus other MOUD options.
The model reported specific staff-hour reductions (318 vs methadone; 747 vs oral buprenorphine; 192 vs weekly extended-release buprenorphine; six vs extended-release naltrexone) and estimated monthly cost savings ranging from $23 to $22,148. The study excluded medication acquisition costs and was funded by Indivior.
Indivior (Nasdaq: INDV) published a national survey of 212 U.S. jails, prisons, and detention centers showing critical access gaps for medications for opioid use disorder (MOUD). Only 58% of facilities offer at least one FDA-approved MOUD, with jails more than twice as likely as prisons to provide treatment.
Regional disparities are stark: western facilities have >3-fold higher odds of offering MOUD than Midwest sites, while the South reports fewer than 10% of diagnosed individuals receiving treatment. Respondents called for better reentry support, telehealth, long-acting injectables, and provider training.
Indivior (Nasdaq: INDV) priced an upsized $450.0 million offering of 0.625% convertible senior notes due 2031, with a 30-day option to purchase an additional $50.0 million.
Net proceeds are estimated at approximately $437.7 million (or ~$486.4 million if option exercised). The initial conversion price is about $41.66 per share, a ~35.0% premium to the March 12, 2026 closing price.
Indivior (Nasdaq: INDV) intends to offer $400 million aggregate principal amount of convertible senior notes due 2031, with a 30-day option for an additional $60 million. Notes will be senior, unsecured, pay semi-annual interest, and may be converted for cash and/or shares.
Indivior expects to use ~$239 million of net proceeds plus ~$102 million cash to repay its term loan and credit facility, up to ~$75 million to repurchase common stock concurrently, and the remainder for general corporate purposes.